CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 30 enrolled
Drug / intervention
Convalescent plasmabiological
Likely dose
Convalescent plasma 200mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04385199
NCT04385199Phase 2Completed
CompareCT.gov

The Use of Convalescent Plasma for Patients Hospitalized With COVID-19 Disease

Henry Ford Health System·interventional·Posted May 12, 2020·Updated May 2, 2022

In Brief

A Phase 2 clinical trial evaluating Convalescent plasma for Coronavirus Infection and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

Pilot study of tolerability and efficacy of transfusion of 200mL of convalescent plasma in patients with COVID-19 respiratory disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Infection, Coronavirus, COVID
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 12, 2020
Enrollment StartMay 4, 2020
Primary CompletionAug 1, 2020
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 6.1 years ago

Interventions

Convalescent plasmabiological

One 200mL transfusion of ABO compatible convalescent plasma over 3 hours